We are live on
!
Find out more
Frazier Life Sciences Management Portfolio holdings
AUM
$4.59B
Turnover
20.45%
1-Year Est. Return
237.58%
This Fund
S&P 500
This Quarter
Est. Return
+34.04%
1 Year Est. Return
+237.58%
3 Year Est. Return
+865.83%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$3.89B
AUM Growth
+$163M
(+4.4%)
Cap. Flow
+$27.4M
Cap. Flow
% of AUM
0.71%
Top 10 Holdings %
Top 10 Hldgs %
73.49%
Holding
43
New
3
Increased
8
Reduced
10
Closed
5
Avg Time Held
1.9
years
Top 10 Avg Time Held
1.8
years
Top 20 Avg Time Held
2.1
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Mirum Pharmaceuticals
MIRM
|
+$83.2M |
| 2 |
BioCryst Pharmaceuticals
BCRX
|
+$31.1M |
| 3 |
Erasca
ERAS
|
+$23M |
| 4 |
Monte Rosa Therapeutics
GLUE
|
+$19.1M |
| 5 |
Palvella Therapeutics
PVLA
|
+$16.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
RNAM
Avidity Biosciences
RNAM
|
+$70.9M |
| 2 |
Abivax
ABVX
|
+$51M |
| 3 |
RAPT Therapeutics
RAPT
|
+$33.3M |
| 4 |
Revolution Medicines
RVMD
|
+$12.3M |
| 5 |
Travere Therapeutics
TVTX
|
+$9.23M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.74% |
| 2 | Miscellaneous | 0.26% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
Mirum Pharmaceuticals
MIRM
$5.19B
| $709M | 18.25% |
7,679,684
+884,563
| +13% | +$83.2M |
2022 Q1
16 quarters
|
|
2
NewAmsterdam Pharma
NAMS
$2.39B
| $542M | 13.96% |
16,943,774
| – | – |
2022 Q4
13 quarters
|
|
|
3
Erasca
ERAS
$5.14B
| $399M | 10.27% |
24,675,188
+1,945,752
| +9% | +$23M |
2024 Q2
7 quarters
|
|
4
BridgeBio Pharma
BBIO
$12.7B
| $256M | 6.59% |
3,448,139
-97,418
| -3% | -$7.06M |
2023 Q1
12 quarters
|
|
5
Arcutis Biotherapeutics
ARQT
$3.32B
| $233M | 5.99% |
9,874,511
| – | – |
2022 Q1
16 quarters
|
|
6
MBX Biosciences
MBX
$2.35B
| $199M | 5.11% |
6,652,013
| – | – |
2024 Q3
6 quarters
|
|
7
Phathom Pharmaceuticals
PHAT
$599M
| $139M | 3.56% |
12,466,489
| – | – |
2022 Q1
16 quarters
|
|
8
Maze Therapeutics
MAZE
$1.46B
| $136M | 3.51% |
4,567,274
| – | – |
2025 Q1
4 quarters
|
|
9
Krystal Biotech
KRYS
$9.79B
| $124M | 3.2% |
481,307
-7,153
| -1% | -$1.9M |
2022 Q1
16 quarters
|
|
10
Trevi Therapeutics
TRVI
$1.72B
| $119M | 3.05% |
9,939,547
-319,862
| -3% | -$3.58M |
2022 Q2
15 quarters
|
|
|
11
Palvella Therapeutics
PVLA
$1.77B
| $110M | 2.83% |
882,400
+160,000
| +22% | +$16.7M |
2024 Q3
6 quarters
|
|
12
DELISTED
KalVista Pharmaceuticals
KALV
| $99.9M | 2.57% |
4,961,108
-78,759
| -2% | -$1.27M |
2022 Q1
16 quarters
|
|
13
Disc Medicine
IRON
$2.14B
| $86.6M | 2.23% |
1,354,852
+94,852
| +8% | +$6.58M |
2023 Q2
11 quarters
|
|
14
Cytokinetics
CYTK
$8.82B
| $76.4M | 1.97% |
1,159,879
+225,237
| +24% | +$14.3M |
2025 Q2
3 quarters
|
|
|
15
Revolution Medicines
RVMD
$41.5B
| $65.7M | 1.69% |
675,686
-121,769
| -15% | -$12.3M |
2023 Q1
12 quarters
|
|
16
Dyne Therapeutics
DYN
$2.81B
| $57.2M | 1.47% |
3,153,082
| – | – |
2025 Q1
4 quarters
|
|
17
Savara
SVRA
$978M
| $53.1M | 1.37% |
9,720,852
-141,449
| -1% | -$787K |
2023 Q3
10 quarters
|
|
18
Tarsus Pharmaceuticals
TARS
$3.38B
| $51.1M | 1.32% |
728,644
| – | – |
2022 Q1
16 quarters
|
|
19
Vor Biopharma
VOR
$1.11B
| $45.4M | 1.17% |
2,543,939
| – | – |
2025 Q4
1 quarter
|
|
20
Agios Pharmaceuticals
AGIO
$1.85B
| $42.5M | 1.09% |
1,256,080
-23,674
| -2% | -$671K |
2023 Q3
10 quarters
|
|
|
21
BioCryst Pharmaceuticals
BCRX
$2.06B
| $38.2M | 0.98% |
+4,009,240
| New | +$31.1M |
2026 Q1
0 quarters
|
|
22
Zai Lab
ZLAB
$2.53B
| $35.8M | 0.92% |
1,902,320
| – | – |
2025 Q1
4 quarters
|
|
23
Aura Biosciences
AURA
$640M
| $34.1M | 0.88% |
5,100,000
| – | – |
2025 Q2
3 quarters
|
|
24
Acadia Pharmaceuticals
ACAD
$3.32B
| $32M | 0.82% |
1,438,198
+141,000
| +11% | +$3.37M |
2025 Q3
2 quarters
|
|
25
Ascendis Pharma A/S
ASND
$14.9B
| $30.5M | 0.78% |
133,333
| – | – |
2024 Q3
6 quarters
|
|
Similar funds
BWA
TYCC
Frazier Life Sciences Management's Q1 2026 Portfolio in Review
As of Q1 2026, Frazier Life Sciences Management held 43 positions worth $3.89B, up 4.4% from $3.72B the previous quarter. Its ten largest holdings account for 73% of the portfolio.
Frazier Life Sciences Management's Q1 2026 filing shows 3 new, 8 increased, 10 reduced and 5 closed positions. Its largest new stake was BioCryst Pharmaceuticals: 4,009,240 shares worth $38.2M. The largest sale was Avidity Biosciences, an estimated $70.9M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Miscellaneous.
- Frazier Life Sciences Management's largest Q1 2026 buy was BioCryst Pharmaceuticals: 4,009,240 shares worth $38.2M.
- Frazier Life Sciences Management added most to Mirum Pharmaceuticals in Q1 2026, an estimated $83.2M increase.
- Frazier Life Sciences Management's biggest Q1 2026 reduction was Revolution Medicines, cutting an estimated $12.3M.
- Frazier Life Sciences Management fully exited Avidity Biosciences in Q1 2026, selling an estimated $70.9M.
- Frazier Life Sciences Management's ten largest holdings make up 73% of its $3.89B portfolio in Q1 2026.
- Frazier Life Sciences Management opened 3 new positions and closed 5 in Q1 2026.
- Frazier Life Sciences Management's portfolio value rose 4.4% quarter-over-quarter to $3.89B.
Based on Frazier Life Sciences Management's 13F filing for Q1 2026, filed 15 May 2026.